nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—KDR—esophageal cancer	0.251	0.553	CbGaD
Sorafenib—ABCC2—esophageal cancer	0.148	0.327	CbGaD
Sorafenib—ABCB1—esophageal cancer	0.0546	0.12	CbGaD
Sorafenib—ABCC2—Carboplatin—esophageal cancer	0.0283	0.136	CbGbCtD
Sorafenib—ABCC4—Methotrexate—esophageal cancer	0.0264	0.126	CbGbCtD
Sorafenib—ABCG2—Carboplatin—esophageal cancer	0.0256	0.123	CbGbCtD
Sorafenib—ABCC2—Cisplatin—esophageal cancer	0.0242	0.116	CbGbCtD
Sorafenib—ABCG2—Cisplatin—esophageal cancer	0.0219	0.105	CbGbCtD
Sorafenib—CYP2C9—Capecitabine—esophageal cancer	0.0161	0.0772	CbGbCtD
Sorafenib—ABCC2—Methotrexate—esophageal cancer	0.0157	0.0752	CbGbCtD
Sorafenib—CYP2B6—Cisplatin—esophageal cancer	0.0154	0.0736	CbGbCtD
Sorafenib—ABCG2—Methotrexate—esophageal cancer	0.0142	0.068	CbGbCtD
Sorafenib—CYP2C9—Cisplatin—esophageal cancer	0.00813	0.0389	CbGbCtD
Sorafenib—ABCB1—Cisplatin—esophageal cancer	0.00789	0.0378	CbGbCtD
Sorafenib—ABCB1—Methotrexate—esophageal cancer	0.00512	0.0245	CbGbCtD
Sorafenib—MAPK15—bronchus—esophageal cancer	0.00226	0.0287	CbGeAlD
Sorafenib—Regorafenib—ABL1—esophageal cancer	0.00215	0.458	CrCbGaD
Sorafenib—Regorafenib—KDR—esophageal cancer	0.00183	0.39	CrCbGaD
Sorafenib—KIT—exocrine gland—esophageal cancer	0.00117	0.0149	CbGeAlD
Sorafenib—ZAK—bronchus—esophageal cancer	0.00114	0.0145	CbGeAlD
Sorafenib—RET—neck—esophageal cancer	0.00114	0.0144	CbGeAlD
Sorafenib—HIPK3—bronchus—esophageal cancer	0.00112	0.0142	CbGeAlD
Sorafenib—TIE1—epithelium—esophageal cancer	0.00106	0.0135	CbGeAlD
Sorafenib—TIE1—smooth muscle tissue—esophageal cancer	0.00102	0.013	CbGeAlD
Sorafenib—FLT1—neck—esophageal cancer	0.001	0.0127	CbGeAlD
Sorafenib—RAF1—neck—esophageal cancer	0.000994	0.0126	CbGeAlD
Sorafenib—ZAK—digestive system—esophageal cancer	0.000881	0.0112	CbGeAlD
Sorafenib—FLT4—epithelium—esophageal cancer	0.000875	0.0111	CbGeAlD
Sorafenib—HIPK3—digestive system—esophageal cancer	0.000862	0.0109	CbGeAlD
Sorafenib—CDK7—lung—esophageal cancer	0.000851	0.0108	CbGeAlD
Sorafenib—FGFR1—bronchus—esophageal cancer	0.00085	0.0108	CbGeAlD
Sorafenib—KDR—neck—esophageal cancer	0.000845	0.0107	CbGeAlD
Sorafenib—TAOK2—lung—esophageal cancer	0.000844	0.0107	CbGeAlD
Sorafenib—MAP3K7—bronchus—esophageal cancer	0.000805	0.0102	CbGeAlD
Sorafenib—MKNK2—epithelium—esophageal cancer	0.000792	0.0101	CbGeAlD
Sorafenib—MAP3K7—smooth muscle tissue—esophageal cancer	0.000787	0.01	CbGeAlD
Sorafenib—MKNK2—bronchus—esophageal cancer	0.00078	0.00991	CbGeAlD
Sorafenib—RET—epithelium—esophageal cancer	0.000773	0.00981	CbGeAlD
Sorafenib—MKNK1—bronchus—esophageal cancer	0.00077	0.00978	CbGeAlD
Sorafenib—MKNK2—smooth muscle tissue—esophageal cancer	0.000763	0.00969	CbGeAlD
Sorafenib—KIT—neck—esophageal cancer	0.000749	0.00951	CbGeAlD
Sorafenib—ZAK—lung—esophageal cancer	0.000736	0.00934	CbGeAlD
Sorafenib—PDGFRB—neck—esophageal cancer	0.000732	0.00929	CbGeAlD
Sorafenib—MAP3K7—trachea—esophageal cancer	0.000723	0.00918	CbGeAlD
Sorafenib—HIPK3—lung—esophageal cancer	0.00072	0.00914	CbGeAlD
Sorafenib—MAP3K19—lung—esophageal cancer	0.000705	0.00896	CbGeAlD
Sorafenib—RALBP1—bronchus—esophageal cancer	0.000704	0.00895	CbGeAlD
Sorafenib—MKNK2—trachea—esophageal cancer	0.0007	0.0089	CbGeAlD
Sorafenib—RALBP1—smooth muscle tissue—esophageal cancer	0.000689	0.00875	CbGeAlD
Sorafenib—FLT1—epithelium—esophageal cancer	0.00068	0.00864	CbGeAlD
Sorafenib—RAF1—epithelium—esophageal cancer	0.000676	0.00859	CbGeAlD
Sorafenib—UGT1A9—digestive system—esophageal cancer	0.000675	0.00858	CbGeAlD
Sorafenib—TIE1—lung—esophageal cancer	0.000673	0.00855	CbGeAlD
Sorafenib—FLT1—bronchus—esophageal cancer	0.00067	0.00851	CbGeAlD
Sorafenib—RAF1—bronchus—esophageal cancer	0.000666	0.00846	CbGeAlD
Sorafenib—EPHB6—bronchus—esophageal cancer	0.000662	0.00841	CbGeAlD
Sorafenib—FLT1—smooth muscle tissue—esophageal cancer	0.000656	0.00833	CbGeAlD
Sorafenib—RAF1—smooth muscle tissue—esophageal cancer	0.000652	0.00828	CbGeAlD
Sorafenib—BRAF—lung—esophageal cancer	0.000645	0.00819	CbGeAlD
Sorafenib—STK10—bronchus—esophageal cancer	0.000634	0.00806	CbGeAlD
Sorafenib—RALBP1—trachea—esophageal cancer	0.000633	0.00803	CbGeAlD
Sorafenib—EPHX2—lung—esophageal cancer	0.000616	0.00783	CbGeAlD
Sorafenib—PDGFRA—smooth muscle tissue—esophageal cancer	0.000614	0.0078	CbGeAlD
Sorafenib—FLT3—lung—esophageal cancer	0.000612	0.00778	CbGeAlD
Sorafenib—Infection—Carboplatin—esophageal cancer	0.000612	0.00609	CcSEcCtD
Sorafenib—MKNK2—digestive system—esophageal cancer	0.000603	0.00765	CbGeAlD
Sorafenib—FLT1—trachea—esophageal cancer	0.000602	0.00764	CbGeAlD
Sorafenib—RAF1—trachea—esophageal cancer	0.000598	0.0076	CbGeAlD
Sorafenib—MKNK1—digestive system—esophageal cancer	0.000595	0.00756	CbGeAlD
Sorafenib—EPHB6—trachea—esophageal cancer	0.000595	0.00755	CbGeAlD
Sorafenib—Haematoma—Capecitabine—esophageal cancer	0.000594	0.00591	CcSEcCtD
Sorafenib—MAPK11—lymph node—esophageal cancer	0.000592	0.00752	CbGeAlD
Sorafenib—RET—digestive system—esophageal cancer	0.000588	0.00746	CbGeAlD
Sorafenib—Respiratory distress—Capecitabine—esophageal cancer	0.000588	0.00585	CcSEcCtD
Sorafenib—CDK7—lymph node—esophageal cancer	0.000582	0.00739	CbGeAlD
Sorafenib—Embolism—Capecitabine—esophageal cancer	0.000581	0.00579	CcSEcCtD
Sorafenib—Hypothyroidism—Capecitabine—esophageal cancer	0.000581	0.00579	CcSEcCtD
Sorafenib—TAOK2—lymph node—esophageal cancer	0.000578	0.00734	CbGeAlD
Sorafenib—KDR—epithelium—esophageal cancer	0.000575	0.00731	CbGeAlD
Sorafenib—Interstitial pneumonia—Methotrexate—esophageal cancer	0.000575	0.00572	CcSEcCtD
Sorafenib—AURKC—lymph node—esophageal cancer	0.000573	0.00728	CbGeAlD
Sorafenib—Leukocytoclastic vasculitis—Methotrexate—esophageal cancer	0.000567	0.00564	CcSEcCtD
Sorafenib—KDR—bronchus—esophageal cancer	0.000566	0.00719	CbGeAlD
Sorafenib—MAP2K5—bronchus—esophageal cancer	0.000566	0.00719	CbGeAlD
Sorafenib—PDGFRA—trachea—esophageal cancer	0.000564	0.00716	CbGeAlD
Sorafenib—FLT4—lung—esophageal cancer	0.000556	0.00706	CbGeAlD
Sorafenib—KDR—smooth muscle tissue—esophageal cancer	0.000554	0.00704	CbGeAlD
Sorafenib—CSF1R—bronchus—esophageal cancer	0.000553	0.00702	CbGeAlD
Sorafenib—FGFR1—lung—esophageal cancer	0.000548	0.00697	CbGeAlD
Sorafenib—RALBP1—digestive system—esophageal cancer	0.000544	0.00691	CbGeAlD
Sorafenib—Haemoglobin decreased—Capecitabine—esophageal cancer	0.000542	0.0054	CcSEcCtD
Sorafenib—CSF1R—smooth muscle tissue—esophageal cancer	0.000541	0.00687	CbGeAlD
Sorafenib—Pain—Carboplatin—esophageal cancer	0.000527	0.00524	CcSEcCtD
Sorafenib—MAP3K7—lung—esophageal cancer	0.000519	0.0066	CbGeAlD
Sorafenib—FLT1—digestive system—esophageal cancer	0.000518	0.00657	CbGeAlD
Sorafenib—RAF1—digestive system—esophageal cancer	0.000515	0.00654	CbGeAlD
Sorafenib—Oropharyngeal discomfort—Capecitabine—esophageal cancer	0.000513	0.00511	CcSEcCtD
Sorafenib—KIT—epithelium—esophageal cancer	0.00051	0.00647	CbGeAlD
Sorafenib—MAP2K5—trachea—esophageal cancer	0.000509	0.00646	CbGeAlD
Sorafenib—KDR—trachea—esophageal cancer	0.000509	0.00646	CbGeAlD
Sorafenib—MKNK2—lung—esophageal cancer	0.000503	0.00639	CbGeAlD
Sorafenib—ZAK—lymph node—esophageal cancer	0.000503	0.00639	CbGeAlD
Sorafenib—KIT—bronchus—esophageal cancer	0.000502	0.00638	CbGeAlD
Sorafenib—Mucosal inflammation—Methotrexate—esophageal cancer	0.000502	0.00499	CcSEcCtD
Sorafenib—PDGFRB—epithelium—esophageal cancer	0.000498	0.00632	CbGeAlD
Sorafenib—MKNK1—lung—esophageal cancer	0.000497	0.00631	CbGeAlD
Sorafenib—CSF1R—trachea—esophageal cancer	0.000496	0.0063	CbGeAlD
Sorafenib—HIPK3—lymph node—esophageal cancer	0.000492	0.00625	CbGeAlD
Sorafenib—KIT—smooth muscle tissue—esophageal cancer	0.000491	0.00624	CbGeAlD
Sorafenib—PDGFRB—bronchus—esophageal cancer	0.00049	0.00623	CbGeAlD
Sorafenib—STK10—digestive system—esophageal cancer	0.00049	0.00622	CbGeAlD
Sorafenib—Pleural effusion—Capecitabine—esophageal cancer	0.000487	0.00485	CcSEcCtD
Sorafenib—Body temperature increased—Carboplatin—esophageal cancer	0.000487	0.00484	CcSEcCtD
Sorafenib—PDGFRA—digestive system—esophageal cancer	0.000485	0.00616	CbGeAlD
Sorafenib—Skin exfoliation—Cisplatin—esophageal cancer	0.000483	0.00481	CcSEcCtD
Sorafenib—PDGFRB—smooth muscle tissue—esophageal cancer	0.00048	0.00609	CbGeAlD
Sorafenib—Neuropathy—Cisplatin—esophageal cancer	0.000475	0.00473	CcSEcCtD
Sorafenib—Myocardial ischaemia—Capecitabine—esophageal cancer	0.000464	0.00462	CcSEcCtD
Sorafenib—UGT1A1—digestive system—esophageal cancer	0.000463	0.00588	CbGeAlD
Sorafenib—Rhinorrhoea—Capecitabine—esophageal cancer	0.000461	0.00458	CcSEcCtD
Sorafenib—TIE1—lymph node—esophageal cancer	0.00046	0.00584	CbGeAlD
Sorafenib—RALBP1—lung—esophageal cancer	0.000454	0.00577	CbGeAlD
Sorafenib—Dysphonia—Capecitabine—esophageal cancer	0.000454	0.00451	CcSEcCtD
Sorafenib—KIT—trachea—esophageal cancer	0.000451	0.00572	CbGeAlD
Sorafenib—Folliculitis—Methotrexate—esophageal cancer	0.000442	0.0044	CcSEcCtD
Sorafenib—BRAF—lymph node—esophageal cancer	0.000441	0.0056	CbGeAlD
Sorafenib—PDGFRB—trachea—esophageal cancer	0.00044	0.00559	CbGeAlD
Sorafenib—KDR—digestive system—esophageal cancer	0.000438	0.00556	CbGeAlD
Sorafenib—Embolism—Methotrexate—esophageal cancer	0.000433	0.00431	CcSEcCtD
Sorafenib—FLT1—lung—esophageal cancer	0.000432	0.00549	CbGeAlD
Sorafenib—RAF1—lung—esophageal cancer	0.00043	0.00546	CbGeAlD
Sorafenib—EPHB6—lung—esophageal cancer	0.000427	0.00543	CbGeAlD
Sorafenib—CSF1R—digestive system—esophageal cancer	0.000427	0.00542	CbGeAlD
Sorafenib—Proteinuria—Capecitabine—esophageal cancer	0.000425	0.00423	CcSEcCtD
Sorafenib—EPHX2—lymph node—esophageal cancer	0.000422	0.00536	CbGeAlD
Sorafenib—Protein urine present—Capecitabine—esophageal cancer	0.000419	0.00417	CcSEcCtD
Sorafenib—FLT3—lymph node—esophageal cancer	0.000419	0.00532	CbGeAlD
Sorafenib—Gastrooesophageal reflux disease—Capecitabine—esophageal cancer	0.000413	0.00411	CcSEcCtD
Sorafenib—STK10—lung—esophageal cancer	0.000409	0.0052	CbGeAlD
Sorafenib—Hypocalcaemia—Capecitabine—esophageal cancer	0.000408	0.00406	CcSEcCtD
Sorafenib—Cardiac failure congestive—Cisplatin—esophageal cancer	0.000405	0.00403	CcSEcCtD
Sorafenib—PDGFRA—lung—esophageal cancer	0.000405	0.00515	CbGeAlD
Sorafenib—Regorafenib—ABCB1—esophageal cancer	0.000398	0.0847	CrCbGaD
Sorafenib—Renal failure acute—Cisplatin—esophageal cancer	0.000398	0.00396	CcSEcCtD
Sorafenib—Blood bilirubin increased—Capecitabine—esophageal cancer	0.000395	0.00393	CcSEcCtD
Sorafenib—Interstitial lung disease—Methotrexate—esophageal cancer	0.000393	0.00391	CcSEcCtD
Sorafenib—ABCC4—bronchus—esophageal cancer	0.00039	0.00496	CbGeAlD
Sorafenib—KIT—digestive system—esophageal cancer	0.000388	0.00493	CbGeAlD
Sorafenib—FLT4—lymph node—esophageal cancer	0.00038	0.00483	CbGeAlD
Sorafenib—HTR2B—smooth muscle tissue—esophageal cancer	0.00038	0.00483	CbGeAlD
Sorafenib—PDGFRB—digestive system—esophageal cancer	0.000379	0.00481	CbGeAlD
Sorafenib—FGFR1—lymph node—esophageal cancer	0.000375	0.00476	CbGeAlD
Sorafenib—Blood pressure increased—Capecitabine—esophageal cancer	0.000373	0.00371	CcSEcCtD
Sorafenib—Hyponatraemia—Cisplatin—esophageal cancer	0.000369	0.00367	CcSEcCtD
Sorafenib—KDR—lung—esophageal cancer	0.000365	0.00464	CbGeAlD
Sorafenib—MAP2K5—lung—esophageal cancer	0.000365	0.00464	CbGeAlD
Sorafenib—Pleural effusion—Methotrexate—esophageal cancer	0.000363	0.00361	CcSEcCtD
Sorafenib—Influenza like illness—Capecitabine—esophageal cancer	0.000362	0.00361	CcSEcCtD
Sorafenib—CSF1R—lung—esophageal cancer	0.000357	0.00453	CbGeAlD
Sorafenib—Skin exfoliation—Capecitabine—esophageal cancer	0.000356	0.00355	CcSEcCtD
Sorafenib—MAP3K7—lymph node—esophageal cancer	0.000355	0.00451	CbGeAlD
Sorafenib—Neuropathy—Capecitabine—esophageal cancer	0.00035	0.00349	CcSEcCtD
Sorafenib—MKNK2—lymph node—esophageal cancer	0.000344	0.00437	CbGeAlD
Sorafenib—Dehydration—Cisplatin—esophageal cancer	0.000342	0.0034	CcSEcCtD
Sorafenib—MKNK1—lymph node—esophageal cancer	0.00034	0.00432	CbGeAlD
Sorafenib—Mouth ulceration—Capecitabine—esophageal cancer	0.000337	0.00336	CcSEcCtD
Sorafenib—Neoplasm—Capecitabine—esophageal cancer	0.000337	0.00336	CcSEcCtD
Sorafenib—RET—lymph node—esophageal cancer	0.000336	0.00426	CbGeAlD
Sorafenib—Hypokalaemia—Cisplatin—esophageal cancer	0.000334	0.00333	CcSEcCtD
Sorafenib—Breast disorder—Cisplatin—esophageal cancer	0.000332	0.00331	CcSEcCtD
Sorafenib—Aspartate aminotransferase increased—Cisplatin—esophageal cancer	0.000331	0.00329	CcSEcCtD
Sorafenib—Nasopharyngitis—Cisplatin—esophageal cancer	0.000329	0.00327	CcSEcCtD
Sorafenib—KIT—lung—esophageal cancer	0.000324	0.00411	CbGeAlD
Sorafenib—PDGFRB—lung—esophageal cancer	0.000316	0.00402	CbGeAlD
Sorafenib—Proteinuria—Methotrexate—esophageal cancer	0.000316	0.00315	CcSEcCtD
Sorafenib—Vismodegib—ABCB1—esophageal cancer	0.000316	0.0672	CrCbGaD
Sorafenib—Protein urine present—Methotrexate—esophageal cancer	0.000312	0.0031	CcSEcCtD
Sorafenib—Pancreatitis—Cisplatin—esophageal cancer	0.000311	0.0031	CcSEcCtD
Sorafenib—RALBP1—lymph node—esophageal cancer	0.000311	0.00395	CbGeAlD
Sorafenib—Hepatic function abnormal—Capecitabine—esophageal cancer	0.00031	0.00308	CcSEcCtD
Sorafenib—Bone disorder—Methotrexate—esophageal cancer	0.000308	0.00306	CcSEcCtD
Sorafenib—Abdominal discomfort—Cisplatin—esophageal cancer	0.000305	0.00303	CcSEcCtD
Sorafenib—ABCC4—digestive system—esophageal cancer	0.000302	0.00383	CbGeAlD
Sorafenib—Glossitis—Methotrexate—esophageal cancer	0.000301	0.003	CcSEcCtD
Sorafenib—Hepatic failure—Capecitabine—esophageal cancer	0.000301	0.003	CcSEcCtD
Sorafenib—HTR2B—digestive system—esophageal cancer	0.0003	0.00381	CbGeAlD
Sorafenib—FLT1—lymph node—esophageal cancer	0.000296	0.00376	CbGeAlD
Sorafenib—RAF1—lymph node—esophageal cancer	0.000294	0.00373	CbGeAlD
Sorafenib—Renal failure acute—Capecitabine—esophageal cancer	0.000293	0.00292	CcSEcCtD
Sorafenib—EPHB6—lymph node—esophageal cancer	0.000292	0.00371	CbGeAlD
Sorafenib—ABCC2—digestive system—esophageal cancer	0.000292	0.00371	CbGeAlD
Sorafenib—Dermatitis exfoliative—Capecitabine—esophageal cancer	0.000287	0.00286	CcSEcCtD
Sorafenib—STK10—lymph node—esophageal cancer	0.00028	0.00355	CbGeAlD
Sorafenib—Acute coronary syndrome—Cisplatin—esophageal cancer	0.000279	0.00278	CcSEcCtD
Sorafenib—Renal failure—Cisplatin—esophageal cancer	0.000278	0.00277	CcSEcCtD
Sorafenib—Neuropathy peripheral—Cisplatin—esophageal cancer	0.000278	0.00276	CcSEcCtD
Sorafenib—Myocardial infarction—Cisplatin—esophageal cancer	0.000278	0.00276	CcSEcCtD
Sorafenib—Cardiac failure—Capecitabine—esophageal cancer	0.000278	0.00276	CcSEcCtD
Sorafenib—PDGFRA—lymph node—esophageal cancer	0.000277	0.00352	CbGeAlD
Sorafenib—Stomatitis—Cisplatin—esophageal cancer	0.000276	0.00275	CcSEcCtD
Sorafenib—Hyponatraemia—Capecitabine—esophageal cancer	0.000272	0.00271	CcSEcCtD
Sorafenib—Pain in extremity—Capecitabine—esophageal cancer	0.000271	0.0027	CcSEcCtD
Sorafenib—Hepatobiliary disease—Cisplatin—esophageal cancer	0.000268	0.00267	CcSEcCtD
Sorafenib—Skin exfoliation—Methotrexate—esophageal cancer	0.000265	0.00264	CcSEcCtD
Sorafenib—Mood swings—Capecitabine—esophageal cancer	0.000257	0.00255	CcSEcCtD
Sorafenib—CYP2B6—bronchus—esophageal cancer	0.000254	0.00323	CbGeAlD
Sorafenib—Dehydration—Capecitabine—esophageal cancer	0.000252	0.00251	CcSEcCtD
Sorafenib—ABCC4—lung—esophageal cancer	0.000252	0.0032	CbGeAlD
Sorafenib—Mouth ulceration—Methotrexate—esophageal cancer	0.000251	0.0025	CcSEcCtD
Sorafenib—Neoplasm—Methotrexate—esophageal cancer	0.000251	0.0025	CcSEcCtD
Sorafenib—Urinary tract disorder—Cisplatin—esophageal cancer	0.000251	0.0025	CcSEcCtD
Sorafenib—CYP2C19—digestive system—esophageal cancer	0.000251	0.00319	CbGeAlD
Sorafenib—HTR2B—lung—esophageal cancer	0.000251	0.00318	CbGeAlD
Sorafenib—MAP2K5—lymph node—esophageal cancer	0.00025	0.00317	CbGeAlD
Sorafenib—KDR—lymph node—esophageal cancer	0.00025	0.00317	CbGeAlD
Sorafenib—Connective tissue disorder—Cisplatin—esophageal cancer	0.00025	0.00249	CcSEcCtD
Sorafenib—Urethral disorder—Cisplatin—esophageal cancer	0.000249	0.00248	CcSEcCtD
Sorafenib—Gynaecomastia—Methotrexate—esophageal cancer	0.000249	0.00247	CcSEcCtD
Sorafenib—Dry skin—Capecitabine—esophageal cancer	0.000248	0.00247	CcSEcCtD
Sorafenib—Abdominal pain upper—Capecitabine—esophageal cancer	0.000247	0.00246	CcSEcCtD
Sorafenib—Hypokalaemia—Capecitabine—esophageal cancer	0.000247	0.00245	CcSEcCtD
Sorafenib—Breast disorder—Capecitabine—esophageal cancer	0.000245	0.00244	CcSEcCtD
Sorafenib—Toxic epidermal necrolysis—Capecitabine—esophageal cancer	0.000244	0.00243	CcSEcCtD
Sorafenib—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	0.000244	0.00243	CcSEcCtD
Sorafenib—CSF1R—lymph node—esophageal cancer	0.000244	0.0031	CbGeAlD
Sorafenib—Nasopharyngitis—Capecitabine—esophageal cancer	0.000242	0.00241	CcSEcCtD
Sorafenib—Gastritis—Capecitabine—esophageal cancer	0.00024	0.00239	CcSEcCtD
Sorafenib—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.000239	0.00238	CcSEcCtD
Sorafenib—Tinnitus—Cisplatin—esophageal cancer	0.000237	0.00236	CcSEcCtD
Sorafenib—Flushing—Cisplatin—esophageal cancer	0.000236	0.00235	CcSEcCtD
Sorafenib—Cardiac disorder—Cisplatin—esophageal cancer	0.000236	0.00235	CcSEcCtD
Sorafenib—Dysphagia—Capecitabine—esophageal cancer	0.000234	0.00233	CcSEcCtD
Sorafenib—Immune system disorder—Cisplatin—esophageal cancer	0.00023	0.00229	CcSEcCtD
Sorafenib—Mediastinal disorder—Cisplatin—esophageal cancer	0.000229	0.00228	CcSEcCtD
Sorafenib—Arrhythmia—Cisplatin—esophageal cancer	0.000227	0.00226	CcSEcCtD
Sorafenib—Alopecia—Cisplatin—esophageal cancer	0.000225	0.00224	CcSEcCtD
Sorafenib—Abdominal discomfort—Capecitabine—esophageal cancer	0.000224	0.00223	CcSEcCtD
Sorafenib—Hepatic failure—Methotrexate—esophageal cancer	0.000224	0.00223	CcSEcCtD
Sorafenib—KIT—lymph node—esophageal cancer	0.000221	0.00281	CbGeAlD
Sorafenib—Malnutrition—Cisplatin—esophageal cancer	0.000221	0.0022	CcSEcCtD
Sorafenib—Erythema—Cisplatin—esophageal cancer	0.000221	0.0022	CcSEcCtD
Sorafenib—Neutropenia—Capecitabine—esophageal cancer	0.000219	0.00218	CcSEcCtD
Sorafenib—Renal failure acute—Methotrexate—esophageal cancer	0.000218	0.00217	CcSEcCtD
Sorafenib—PDGFRB—lymph node—esophageal cancer	0.000216	0.00275	CbGeAlD
Sorafenib—Dermatitis exfoliative—Methotrexate—esophageal cancer	0.000214	0.00213	CcSEcCtD
Sorafenib—Muscle spasms—Cisplatin—esophageal cancer	0.000213	0.00212	CcSEcCtD
Sorafenib—Weight decreased—Capecitabine—esophageal cancer	0.000212	0.00211	CcSEcCtD
Sorafenib—Pneumonia—Capecitabine—esophageal cancer	0.00021	0.00209	CcSEcCtD
Sorafenib—Infestation—Capecitabine—esophageal cancer	0.000209	0.00208	CcSEcCtD
Sorafenib—Infestation NOS—Capecitabine—esophageal cancer	0.000209	0.00208	CcSEcCtD
Sorafenib—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.000207	0.00206	CcSEcCtD
Sorafenib—Acute coronary syndrome—Capecitabine—esophageal cancer	0.000206	0.00205	CcSEcCtD
Sorafenib—Renal failure—Capecitabine—esophageal cancer	0.000205	0.00204	CcSEcCtD
Sorafenib—CYP1A2—digestive system—esophageal cancer	0.000205	0.0026	CbGeAlD
Sorafenib—Myocardial infarction—Capecitabine—esophageal cancer	0.000205	0.00204	CcSEcCtD
Sorafenib—Neuropathy peripheral—Capecitabine—esophageal cancer	0.000205	0.00204	CcSEcCtD
Sorafenib—Anaemia—Cisplatin—esophageal cancer	0.000205	0.00204	CcSEcCtD
Sorafenib—Jaundice—Capecitabine—esophageal cancer	0.000204	0.00203	CcSEcCtD
Sorafenib—Stomatitis—Capecitabine—esophageal cancer	0.000204	0.00203	CcSEcCtD
Sorafenib—Leukopenia—Cisplatin—esophageal cancer	0.000198	0.00197	CcSEcCtD
Sorafenib—CYP3A5—digestive system—esophageal cancer	0.000198	0.00251	CbGeAlD
Sorafenib—Hepatobiliary disease—Capecitabine—esophageal cancer	0.000197	0.00196	CcSEcCtD
Sorafenib—Epistaxis—Capecitabine—esophageal cancer	0.000197	0.00196	CcSEcCtD
Sorafenib—CYP2B6—digestive system—esophageal cancer	0.000196	0.00249	CbGeAlD
Sorafenib—CYP2C9—digestive system—esophageal cancer	0.000194	0.00247	CbGeAlD
Sorafenib—Mood swings—Methotrexate—esophageal cancer	0.000191	0.0019	CcSEcCtD
Sorafenib—Myalgia—Cisplatin—esophageal cancer	0.000188	0.00188	CcSEcCtD
Sorafenib—Haemoglobin—Capecitabine—esophageal cancer	0.000188	0.00187	CcSEcCtD
Sorafenib—Haemorrhage—Capecitabine—esophageal cancer	0.000187	0.00187	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000187	0.00186	CcSEcCtD
Sorafenib—Urinary tract disorder—Capecitabine—esophageal cancer	0.000185	0.00184	CcSEcCtD
Sorafenib—Connective tissue disorder—Capecitabine—esophageal cancer	0.000184	0.00183	CcSEcCtD
Sorafenib—Urethral disorder—Capecitabine—esophageal cancer	0.000184	0.00183	CcSEcCtD
Sorafenib—Breast disorder—Methotrexate—esophageal cancer	0.000182	0.00181	CcSEcCtD
Sorafenib—Toxic epidermal necrolysis—Methotrexate—esophageal cancer	0.000182	0.00181	CcSEcCtD
Sorafenib—Anaphylactic shock—Cisplatin—esophageal cancer	0.000181	0.0018	CcSEcCtD
Sorafenib—Infection—Cisplatin—esophageal cancer	0.000179	0.00179	CcSEcCtD
Sorafenib—ABCG2—lung—esophageal cancer	0.000178	0.00226	CbGeAlD
Sorafenib—Erythema multiforme—Capecitabine—esophageal cancer	0.000177	0.00176	CcSEcCtD
Sorafenib—Nervous system disorder—Cisplatin—esophageal cancer	0.000177	0.00176	CcSEcCtD
Sorafenib—Thrombocytopenia—Cisplatin—esophageal cancer	0.000177	0.00176	CcSEcCtD
Sorafenib—Skin disorder—Cisplatin—esophageal cancer	0.000175	0.00175	CcSEcCtD
Sorafenib—Tinnitus—Capecitabine—esophageal cancer	0.000175	0.00174	CcSEcCtD
Sorafenib—Cardiac disorder—Capecitabine—esophageal cancer	0.000174	0.00173	CcSEcCtD
Sorafenib—Flushing—Capecitabine—esophageal cancer	0.000174	0.00173	CcSEcCtD
Sorafenib—ABCC4—lymph node—esophageal cancer	0.000172	0.00219	CbGeAlD
Sorafenib—Anorexia—Cisplatin—esophageal cancer	0.000172	0.00171	CcSEcCtD
Sorafenib—HTR2B—lymph node—esophageal cancer	0.000171	0.00218	CbGeAlD
Sorafenib—CYP1A2—lung—esophageal cancer	0.000171	0.00217	CbGeAlD
Sorafenib—Pancreatitis—Methotrexate—esophageal cancer	0.000171	0.0017	CcSEcCtD
Sorafenib—Angiopathy—Capecitabine—esophageal cancer	0.00017	0.00169	CcSEcCtD
Sorafenib—Immune system disorder—Capecitabine—esophageal cancer	0.000169	0.00168	CcSEcCtD
Sorafenib—Mediastinal disorder—Capecitabine—esophageal cancer	0.000169	0.00168	CcSEcCtD
Sorafenib—Arrhythmia—Capecitabine—esophageal cancer	0.000167	0.00167	CcSEcCtD
Sorafenib—Abdominal discomfort—Methotrexate—esophageal cancer	0.000167	0.00166	CcSEcCtD
Sorafenib—ABCC2—lymph node—esophageal cancer	0.000167	0.00212	CbGeAlD
Sorafenib—Alopecia—Capecitabine—esophageal cancer	0.000166	0.00165	CcSEcCtD
Sorafenib—CYP3A5—lung—esophageal cancer	0.000165	0.0021	CbGeAlD
Sorafenib—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000165	0.00164	CcSEcCtD
Sorafenib—Mental disorder—Capecitabine—esophageal cancer	0.000164	0.00163	CcSEcCtD
Sorafenib—CYP2B6—lung—esophageal cancer	0.000164	0.00208	CbGeAlD
Sorafenib—Malnutrition—Capecitabine—esophageal cancer	0.000163	0.00162	CcSEcCtD
Sorafenib—Erythema—Capecitabine—esophageal cancer	0.000163	0.00162	CcSEcCtD
Sorafenib—Neutropenia—Methotrexate—esophageal cancer	0.000163	0.00162	CcSEcCtD
Sorafenib—Dyspnoea—Cisplatin—esophageal cancer	0.000161	0.0016	CcSEcCtD
Sorafenib—Erectile dysfunction—Methotrexate—esophageal cancer	0.000161	0.0016	CcSEcCtD
Sorafenib—Dysgeusia—Capecitabine—esophageal cancer	0.00016	0.00159	CcSEcCtD
Sorafenib—Decreased appetite—Cisplatin—esophageal cancer	0.000157	0.00156	CcSEcCtD
Sorafenib—Muscle spasms—Capecitabine—esophageal cancer	0.000157	0.00156	CcSEcCtD
Sorafenib—Pneumonia—Methotrexate—esophageal cancer	0.000156	0.00156	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000156	0.00155	CcSEcCtD
Sorafenib—Infestation NOS—Methotrexate—esophageal cancer	0.000155	0.00155	CcSEcCtD
Sorafenib—Infestation—Methotrexate—esophageal cancer	0.000155	0.00155	CcSEcCtD
Sorafenib—Pain—Cisplatin—esophageal cancer	0.000154	0.00154	CcSEcCtD
Sorafenib—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.000154	0.00153	CcSEcCtD
Sorafenib—Renal failure—Methotrexate—esophageal cancer	0.000153	0.00152	CcSEcCtD
Sorafenib—Stomatitis—Methotrexate—esophageal cancer	0.000151	0.00151	CcSEcCtD
Sorafenib—Anaemia—Capecitabine—esophageal cancer	0.000151	0.0015	CcSEcCtD
Sorafenib—CYP3A4—digestive system—esophageal cancer	0.000148	0.00188	CbGeAlD
Sorafenib—Hepatobiliary disease—Methotrexate—esophageal cancer	0.000147	0.00146	CcSEcCtD
Sorafenib—Epistaxis—Methotrexate—esophageal cancer	0.000147	0.00146	CcSEcCtD
Sorafenib—Syncope—Capecitabine—esophageal cancer	0.000146	0.00146	CcSEcCtD
Sorafenib—Leukopenia—Capecitabine—esophageal cancer	0.000146	0.00145	CcSEcCtD
Sorafenib—CYP2D6—digestive system—esophageal cancer	0.000146	0.00185	CbGeAlD
Sorafenib—Loss of consciousness—Capecitabine—esophageal cancer	0.000143	0.00143	CcSEcCtD
Sorafenib—Body temperature increased—Cisplatin—esophageal cancer	0.000143	0.00142	CcSEcCtD
Sorafenib—Cough—Capecitabine—esophageal cancer	0.000142	0.00142	CcSEcCtD
Sorafenib—Hypertension—Capecitabine—esophageal cancer	0.000141	0.0014	CcSEcCtD
Sorafenib—Haemoglobin—Methotrexate—esophageal cancer	0.00014	0.0014	CcSEcCtD
Sorafenib—Haemorrhage—Methotrexate—esophageal cancer	0.00014	0.00139	CcSEcCtD
Sorafenib—Myalgia—Capecitabine—esophageal cancer	0.000139	0.00138	CcSEcCtD
Sorafenib—Arthralgia—Capecitabine—esophageal cancer	0.000139	0.00138	CcSEcCtD
Sorafenib—ABCB1—epithelium—esophageal cancer	0.000138	0.00175	CbGeAlD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000138	0.00137	CcSEcCtD
Sorafenib—Urinary tract disorder—Methotrexate—esophageal cancer	0.000138	0.00137	CcSEcCtD
Sorafenib—Urethral disorder—Methotrexate—esophageal cancer	0.000137	0.00136	CcSEcCtD
Sorafenib—Dry mouth—Capecitabine—esophageal cancer	0.000136	0.00135	CcSEcCtD
Sorafenib—Hypersensitivity—Cisplatin—esophageal cancer	0.000133	0.00132	CcSEcCtD
Sorafenib—Infection—Capecitabine—esophageal cancer	0.000132	0.00132	CcSEcCtD
Sorafenib—Erythema multiforme—Methotrexate—esophageal cancer	0.000132	0.00131	CcSEcCtD
Sorafenib—Shock—Capecitabine—esophageal cancer	0.000131	0.0013	CcSEcCtD
Sorafenib—Nervous system disorder—Capecitabine—esophageal cancer	0.000131	0.0013	CcSEcCtD
Sorafenib—Thrombocytopenia—Capecitabine—esophageal cancer	0.00013	0.0013	CcSEcCtD
Sorafenib—Tinnitus—Methotrexate—esophageal cancer	0.00013	0.00129	CcSEcCtD
Sorafenib—Asthenia—Cisplatin—esophageal cancer	0.00013	0.00129	CcSEcCtD
Sorafenib—Cardiac disorder—Methotrexate—esophageal cancer	0.000129	0.00129	CcSEcCtD
Sorafenib—Skin disorder—Capecitabine—esophageal cancer	0.000129	0.00129	CcSEcCtD
Sorafenib—Anorexia—Capecitabine—esophageal cancer	0.000127	0.00126	CcSEcCtD
Sorafenib—Angiopathy—Methotrexate—esophageal cancer	0.000127	0.00126	CcSEcCtD
Sorafenib—Immune system disorder—Methotrexate—esophageal cancer	0.000126	0.00125	CcSEcCtD
Sorafenib—Mediastinal disorder—Methotrexate—esophageal cancer	0.000126	0.00125	CcSEcCtD
Sorafenib—Diarrhoea—Cisplatin—esophageal cancer	0.000124	0.00123	CcSEcCtD
Sorafenib—Alopecia—Methotrexate—esophageal cancer	0.000123	0.00123	CcSEcCtD
Sorafenib—Mental disorder—Methotrexate—esophageal cancer	0.000122	0.00122	CcSEcCtD
Sorafenib—ABCB1—trachea—esophageal cancer	0.000122	0.00155	CbGeAlD
Sorafenib—ABCG2—lymph node—esophageal cancer	0.000122	0.00154	CbGeAlD
Sorafenib—Malnutrition—Methotrexate—esophageal cancer	0.000121	0.00121	CcSEcCtD
Sorafenib—Erythema—Methotrexate—esophageal cancer	0.000121	0.00121	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000121	0.00121	CcSEcCtD
Sorafenib—Dysgeusia—Methotrexate—esophageal cancer	0.000119	0.00118	CcSEcCtD
Sorafenib—Dyspnoea—Capecitabine—esophageal cancer	0.000119	0.00118	CcSEcCtD
Sorafenib—Dyspepsia—Capecitabine—esophageal cancer	0.000117	0.00117	CcSEcCtD
Sorafenib—Decreased appetite—Capecitabine—esophageal cancer	0.000116	0.00115	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000115	0.00114	CcSEcCtD
Sorafenib—Vomiting—Cisplatin—esophageal cancer	0.000115	0.00114	CcSEcCtD
Sorafenib—Fatigue—Capecitabine—esophageal cancer	0.000115	0.00114	CcSEcCtD
Sorafenib—Rash—Cisplatin—esophageal cancer	0.000114	0.00113	CcSEcCtD
Sorafenib—Constipation—Capecitabine—esophageal cancer	0.000114	0.00113	CcSEcCtD
Sorafenib—Pain—Capecitabine—esophageal cancer	0.000114	0.00113	CcSEcCtD
Sorafenib—Dermatitis—Cisplatin—esophageal cancer	0.000114	0.00113	CcSEcCtD
Sorafenib—Anaemia—Methotrexate—esophageal cancer	0.000112	0.00112	CcSEcCtD
Sorafenib—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000109	0.00108	CcSEcCtD
Sorafenib—Leukopenia—Methotrexate—esophageal cancer	0.000109	0.00108	CcSEcCtD
Sorafenib—Nausea—Cisplatin—esophageal cancer	0.000107	0.00107	CcSEcCtD
Sorafenib—Cough—Methotrexate—esophageal cancer	0.000106	0.00105	CcSEcCtD
Sorafenib—Urticaria—Capecitabine—esophageal cancer	0.000106	0.00105	CcSEcCtD
Sorafenib—Abdominal pain—Capecitabine—esophageal cancer	0.000105	0.00105	CcSEcCtD
Sorafenib—Body temperature increased—Capecitabine—esophageal cancer	0.000105	0.00105	CcSEcCtD
Sorafenib—ABCB1—digestive system—esophageal cancer	0.000105	0.00133	CbGeAlD
Sorafenib—Arthralgia—Methotrexate—esophageal cancer	0.000103	0.00103	CcSEcCtD
Sorafenib—Myalgia—Methotrexate—esophageal cancer	0.000103	0.00103	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000103	0.00102	CcSEcCtD
Sorafenib—Anaphylactic shock—Methotrexate—esophageal cancer	9.91e-05	0.000986	CcSEcCtD
Sorafenib—Infection—Methotrexate—esophageal cancer	9.85e-05	0.00098	CcSEcCtD
Sorafenib—Hypersensitivity—Capecitabine—esophageal cancer	9.81e-05	0.000976	CcSEcCtD
Sorafenib—Nervous system disorder—Methotrexate—esophageal cancer	9.72e-05	0.000967	CcSEcCtD
Sorafenib—Thrombocytopenia—Methotrexate—esophageal cancer	9.71e-05	0.000966	CcSEcCtD
Sorafenib—Skin disorder—Methotrexate—esophageal cancer	9.63e-05	0.000958	CcSEcCtD
Sorafenib—Asthenia—Capecitabine—esophageal cancer	9.55e-05	0.000951	CcSEcCtD
Sorafenib—Anorexia—Methotrexate—esophageal cancer	9.45e-05	0.00094	CcSEcCtD
Sorafenib—Pruritus—Capecitabine—esophageal cancer	9.42e-05	0.000937	CcSEcCtD
Sorafenib—Diarrhoea—Capecitabine—esophageal cancer	9.11e-05	0.000907	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Methotrexate—esophageal cancer	9.03e-05	0.000899	CcSEcCtD
Sorafenib—Dyspnoea—Methotrexate—esophageal cancer	8.84e-05	0.000879	CcSEcCtD
Sorafenib—Dizziness—Capecitabine—esophageal cancer	8.81e-05	0.000876	CcSEcCtD
Sorafenib—ABCB1—lung—esophageal cancer	8.77e-05	0.00111	CbGeAlD
Sorafenib—Dyspepsia—Methotrexate—esophageal cancer	8.73e-05	0.000868	CcSEcCtD
Sorafenib—Decreased appetite—Methotrexate—esophageal cancer	8.62e-05	0.000857	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Methotrexate—esophageal cancer	8.56e-05	0.000852	CcSEcCtD
Sorafenib—Fatigue—Methotrexate—esophageal cancer	8.55e-05	0.00085	CcSEcCtD
Sorafenib—Pain—Methotrexate—esophageal cancer	8.48e-05	0.000844	CcSEcCtD
Sorafenib—Vomiting—Capecitabine—esophageal cancer	8.47e-05	0.000842	CcSEcCtD
Sorafenib—Rash—Capecitabine—esophageal cancer	8.4e-05	0.000835	CcSEcCtD
Sorafenib—Dermatitis—Capecitabine—esophageal cancer	8.39e-05	0.000835	CcSEcCtD
Sorafenib—Headache—Capecitabine—esophageal cancer	8.34e-05	0.00083	CcSEcCtD
Sorafenib—Gastrointestinal pain—Methotrexate—esophageal cancer	8.11e-05	0.000807	CcSEcCtD
Sorafenib—Nausea—Capecitabine—esophageal cancer	7.91e-05	0.000787	CcSEcCtD
Sorafenib—Urticaria—Methotrexate—esophageal cancer	7.87e-05	0.000784	CcSEcCtD
Sorafenib—Abdominal pain—Methotrexate—esophageal cancer	7.84e-05	0.00078	CcSEcCtD
Sorafenib—Body temperature increased—Methotrexate—esophageal cancer	7.84e-05	0.00078	CcSEcCtD
Sorafenib—Hypersensitivity—Methotrexate—esophageal cancer	7.3e-05	0.000727	CcSEcCtD
Sorafenib—Asthenia—Methotrexate—esophageal cancer	7.11e-05	0.000708	CcSEcCtD
Sorafenib—Pruritus—Methotrexate—esophageal cancer	7.01e-05	0.000698	CcSEcCtD
Sorafenib—Diarrhoea—Methotrexate—esophageal cancer	6.78e-05	0.000675	CcSEcCtD
Sorafenib—Dizziness—Methotrexate—esophageal cancer	6.55e-05	0.000652	CcSEcCtD
Sorafenib—Vomiting—Methotrexate—esophageal cancer	6.3e-05	0.000627	CcSEcCtD
Sorafenib—Rash—Methotrexate—esophageal cancer	6.25e-05	0.000622	CcSEcCtD
Sorafenib—Dermatitis—Methotrexate—esophageal cancer	6.24e-05	0.000621	CcSEcCtD
Sorafenib—Headache—Methotrexate—esophageal cancer	6.21e-05	0.000618	CcSEcCtD
Sorafenib—ABCB1—lymph node—esophageal cancer	6e-05	0.000762	CbGeAlD
Sorafenib—Nausea—Methotrexate—esophageal cancer	5.89e-05	0.000586	CcSEcCtD
Sorafenib—UGT1A9—Metabolism—NOS3—esophageal cancer	2.42e-06	1.58e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CYP26A1—esophageal cancer	2.41e-06	1.58e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—EP300—esophageal cancer	2.4e-06	1.57e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—EGFR—esophageal cancer	2.39e-06	1.56e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—CCND1—esophageal cancer	2.37e-06	1.55e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ALDH2—esophageal cancer	2.37e-06	1.55e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ALOX15—esophageal cancer	2.35e-06	1.54e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CREBBP—esophageal cancer	2.35e-06	1.53e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—CCND1—esophageal cancer	2.35e-06	1.53e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	2.33e-06	1.52e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—MYC—esophageal cancer	2.32e-06	1.52e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—HIF1A—esophageal cancer	2.32e-06	1.52e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—MYC—esophageal cancer	2.32e-06	1.51e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—EP300—esophageal cancer	2.31e-06	1.51e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—EGFR—esophageal cancer	2.31e-06	1.51e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—CYP1B1—esophageal cancer	2.3e-06	1.51e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—ERBB2—esophageal cancer	2.3e-06	1.5e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—CDKN1A—esophageal cancer	2.29e-06	1.5e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—CREBBP—esophageal cancer	2.29e-06	1.5e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—ERBB2—esophageal cancer	2.29e-06	1.5e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—PIK3CA—esophageal cancer	2.28e-06	1.49e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—EGFR—esophageal cancer	2.27e-06	1.48e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—CDKN1A—esophageal cancer	2.27e-06	1.48e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—CREBBP—esophageal cancer	2.27e-06	1.48e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—MYC—esophageal cancer	2.27e-06	1.48e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—EGFR—esophageal cancer	2.27e-06	1.48e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GSTT1—esophageal cancer	2.25e-06	1.47e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—PIK3CA—esophageal cancer	2.25e-06	1.47e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—PIK3CA—esophageal cancer	2.25e-06	1.47e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—CYP1B1—esophageal cancer	2.25e-06	1.47e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—CDKN1A—esophageal cancer	2.24e-06	1.47e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GSTO1—esophageal cancer	2.24e-06	1.47e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—TPI1—esophageal cancer	2.24e-06	1.47e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CYP2A6—esophageal cancer	2.23e-06	1.46e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	2.22e-06	1.45e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—KDR—esophageal cancer	2.22e-06	1.45e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—EGFR—esophageal cancer	2.22e-06	1.45e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—HMOX1—esophageal cancer	2.22e-06	1.45e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—EGFR—esophageal cancer	2.21e-06	1.44e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—MYC—esophageal cancer	2.21e-06	1.44e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—PTGS2—esophageal cancer	2.21e-06	1.44e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—PTGS2—esophageal cancer	2.21e-06	1.44e-05	CbGpPWpGaD
Sorafenib—HTR2B—GPCR downstream signaling—PIK3CA—esophageal cancer	2.21e-06	1.44e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—NOS3—esophageal cancer	2.21e-06	1.44e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CREBBP—esophageal cancer	2.2e-06	1.43e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—EP300—esophageal cancer	2.18e-06	1.43e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	2.17e-06	1.42e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—CYP19A1—esophageal cancer	2.17e-06	1.42e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—EGFR—esophageal cancer	2.16e-06	1.41e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—EP300—esophageal cancer	2.16e-06	1.41e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—EGFR—esophageal cancer	2.16e-06	1.41e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ALDOB—esophageal cancer	2.15e-06	1.41e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—CCND1—esophageal cancer	2.14e-06	1.4e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—CCND1—esophageal cancer	2.14e-06	1.4e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—PIK3CA—esophageal cancer	2.14e-06	1.4e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—EP300—esophageal cancer	2.14e-06	1.39e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—PIK3CA—esophageal cancer	2.13e-06	1.39e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	2.13e-06	1.39e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—ABCB1—esophageal cancer	2.13e-06	1.39e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—CYP1B1—esophageal cancer	2.12e-06	1.38e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—CYP19A1—esophageal cancer	2.12e-06	1.38e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ENO1—esophageal cancer	2.11e-06	1.38e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PTGS1—esophageal cancer	2.11e-06	1.38e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—NOS3—esophageal cancer	2.1e-06	1.37e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—CYP1B1—esophageal cancer	2.1e-06	1.37e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—NOTCH1—esophageal cancer	2.09e-06	1.37e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—MYC—esophageal cancer	2.09e-06	1.36e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PSME2—esophageal cancer	2.08e-06	1.36e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PSME1—esophageal cancer	2.08e-06	1.36e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—PIK3CA—esophageal cancer	2.08e-06	1.36e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GAPDH—esophageal cancer	2.07e-06	1.35e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—CDKN1A—esophageal cancer	2.07e-06	1.35e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—CDKN1A—esophageal cancer	2.07e-06	1.35e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—ERBB2—esophageal cancer	2.06e-06	1.35e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CRABP1—esophageal cancer	2.05e-06	1.34e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—NOS3—esophageal cancer	2.05e-06	1.34e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—EGFR—esophageal cancer	2.04e-06	1.33e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—NOS3—esophageal cancer	2.03e-06	1.33e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—CCND1—esophageal cancer	2.03e-06	1.32e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—CCND1—esophageal cancer	2.02e-06	1.32e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—PIK3CA—esophageal cancer	2e-06	1.31e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—CYP19A1—esophageal cancer	1.99e-06	1.3e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—HMOX1—esophageal cancer	1.98e-06	1.29e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—CYP19A1—esophageal cancer	1.98e-06	1.29e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—PIK3CA—esophageal cancer	1.97e-06	1.29e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—EGFR—esophageal cancer	1.97e-06	1.29e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—ERBB2—esophageal cancer	1.97e-06	1.29e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—EP300—esophageal cancer	1.97e-06	1.29e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—EP300—esophageal cancer	1.97e-06	1.29e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—PIK3CA—esophageal cancer	1.97e-06	1.29e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—NOS3—esophageal cancer	1.97e-06	1.28e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—CDKN1A—esophageal cancer	1.96e-06	1.28e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—CDKN1A—esophageal cancer	1.96e-06	1.28e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GNG7—esophageal cancer	1.95e-06	1.28e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.94e-06	1.27e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—HMOX1—esophageal cancer	1.93e-06	1.26e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—PIK3CA—esophageal cancer	1.93e-06	1.26e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—PIK3CA—esophageal cancer	1.92e-06	1.25e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—MYC—esophageal cancer	1.9e-06	1.24e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—ABCB1—esophageal cancer	1.9e-06	1.24e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CREBBP—esophageal cancer	1.9e-06	1.24e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—MYC—esophageal cancer	1.88e-06	1.23e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—PIK3CA—esophageal cancer	1.88e-06	1.23e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—PTGS2—esophageal cancer	1.88e-06	1.23e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—PIK3CA—esophageal cancer	1.87e-06	1.22e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—EP300—esophageal cancer	1.87e-06	1.22e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—TP53—esophageal cancer	1.86e-06	1.22e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—EGFR—esophageal cancer	1.86e-06	1.22e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—EP300—esophageal cancer	1.86e-06	1.22e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—MYC—esophageal cancer	1.86e-06	1.22e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—EGFR—esophageal cancer	1.86e-06	1.21e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—PTGS2—esophageal cancer	1.86e-06	1.21e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—EGFR—esophageal cancer	1.84e-06	1.2e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—ERBB2—esophageal cancer	1.84e-06	1.2e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—EP300—esophageal cancer	1.84e-06	1.2e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—EP300—esophageal cancer	1.84e-06	1.2e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ALDH2—esophageal cancer	1.83e-06	1.19e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CCND1—esophageal cancer	1.82e-06	1.19e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—EGFR—esophageal cancer	1.82e-06	1.19e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—HMOX1—esophageal cancer	1.82e-06	1.19e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.82e-06	1.19e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—TP53—esophageal cancer	1.82e-06	1.19e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—HMOX1—esophageal cancer	1.8e-06	1.18e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CYP1B1—esophageal cancer	1.8e-06	1.17e-05	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—PIK3CA—esophageal cancer	1.78e-06	1.16e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—PIK3CA—esophageal cancer	1.77e-06	1.16e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.77e-06	1.16e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CDKN1A—esophageal cancer	1.76e-06	1.15e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—ABCB1—esophageal cancer	1.75e-06	1.14e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GSTT1—esophageal cancer	1.74e-06	1.14e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CCND1—esophageal cancer	1.74e-06	1.14e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—ABCB1—esophageal cancer	1.73e-06	1.13e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CYP2A6—esophageal cancer	1.72e-06	1.12e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—MYC—esophageal cancer	1.71e-06	1.12e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—MYC—esophageal cancer	1.71e-06	1.12e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—PIK3CA—esophageal cancer	1.71e-06	1.12e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—NOS3—esophageal cancer	1.7e-06	1.11e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CYP19A1—esophageal cancer	1.69e-06	1.1e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CDKN1A—esophageal cancer	1.68e-06	1.1e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—CREBBP—esophageal cancer	1.68e-06	1.1e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—EP300—esophageal cancer	1.68e-06	1.1e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—EGFR—esophageal cancer	1.68e-06	1.1e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—EGFR—esophageal cancer	1.68e-06	1.1e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—CREBBP—esophageal cancer	1.64e-06	1.07e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PTGS1—esophageal cancer	1.63e-06	1.06e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ENO1—esophageal cancer	1.63e-06	1.06e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—MYC—esophageal cancer	1.63e-06	1.06e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CCND1—esophageal cancer	1.62e-06	1.06e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—MYC—esophageal cancer	1.62e-06	1.06e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—PIK3CA—esophageal cancer	1.62e-06	1.06e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—PIK3CA—esophageal cancer	1.61e-06	1.05e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.61e-06	1.05e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PSME1—esophageal cancer	1.61e-06	1.05e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PSME2—esophageal cancer	1.61e-06	1.05e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—EP300—esophageal cancer	1.6e-06	1.05e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—PIK3CA—esophageal cancer	1.6e-06	1.04e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—EGFR—esophageal cancer	1.59e-06	1.04e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—EGFR—esophageal cancer	1.59e-06	1.04e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—ERBB2—esophageal cancer	1.59e-06	1.04e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—PIK3CA—esophageal cancer	1.58e-06	1.03e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CDKN1A—esophageal cancer	1.57e-06	1.03e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—TP53—esophageal cancer	1.56e-06	1.02e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—EP300—esophageal cancer	1.56e-06	1.02e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—TP53—esophageal cancer	1.55e-06	1.01e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—EP300—esophageal cancer	1.55e-06	1.01e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—HMOX1—esophageal cancer	1.54e-06	1.01e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.51e-06	9.87e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—NOS3—esophageal cancer	1.5e-06	9.82e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—EP300—esophageal cancer	1.5e-06	9.77e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ABCB1—esophageal cancer	1.48e-06	9.66e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—NOS3—esophageal cancer	1.47e-06	9.6e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MYC—esophageal cancer	1.46e-06	9.55e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—PIK3CA—esophageal cancer	1.46e-06	9.51e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—PIK3CA—esophageal cancer	1.46e-06	9.51e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.44e-06	9.38e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—EGFR—esophageal cancer	1.43e-06	9.34e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—CREBBP—esophageal cancer	1.42e-06	9.28e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TP53—esophageal cancer	1.41e-06	9.2e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TP53—esophageal cancer	1.41e-06	9.2e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CCND1—esophageal cancer	1.4e-06	9.16e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MYC—esophageal cancer	1.39e-06	9.11e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CYP1B1—esophageal cancer	1.39e-06	9.05e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—PIK3CA—esophageal cancer	1.38e-06	9.02e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—PIK3CA—esophageal cancer	1.38e-06	9e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PTGS2—esophageal cancer	1.37e-06	8.98e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—EGFR—esophageal cancer	1.36e-06	8.91e-06	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—PIK3CA—esophageal cancer	1.36e-06	8.88e-06	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—PIK3CA—esophageal cancer	1.36e-06	8.88e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CDKN1A—esophageal cancer	1.36e-06	8.86e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PTGS2—esophageal cancer	1.34e-06	8.78e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TP53—esophageal cancer	1.34e-06	8.73e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TP53—esophageal cancer	1.33e-06	8.71e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.31e-06	8.55e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CYP19A1—esophageal cancer	1.3e-06	8.51e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MYC—esophageal cancer	1.3e-06	8.51e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—EP300—esophageal cancer	1.29e-06	8.43e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—EGFR—esophageal cancer	1.27e-06	8.33e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—NOS3—esophageal cancer	1.27e-06	8.31e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—CREBBP—esophageal cancer	1.27e-06	8.29e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—PIK3CA—esophageal cancer	1.24e-06	8.11e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—CREBBP—esophageal cancer	1.24e-06	8.09e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TP53—esophageal cancer	1.2e-06	7.84e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—HMOX1—esophageal cancer	1.19e-06	7.77e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—PIK3CA—esophageal cancer	1.18e-06	7.73e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—CREBBP—esophageal cancer	1.17e-06	7.62e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PTGS2—esophageal cancer	1.16e-06	7.6e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—CREBBP—esophageal cancer	1.16e-06	7.56e-06	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—PIK3CA—esophageal cancer	1.15e-06	7.54e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TP53—esophageal cancer	1.14e-06	7.48e-06	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—PIK3CA—esophageal cancer	1.14e-06	7.47e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—EP300—esophageal cancer	1.14e-06	7.47e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ABCB1—esophageal cancer	1.14e-06	7.46e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—NOS3—esophageal cancer	1.14e-06	7.42e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MYC—esophageal cancer	1.12e-06	7.35e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.12e-06	7.3e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—EP300—esophageal cancer	1.12e-06	7.3e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—NOS3—esophageal cancer	1.11e-06	7.24e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—PIK3CA—esophageal cancer	1.11e-06	7.23e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—EGFR—esophageal cancer	1.1e-06	7.19e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TP53—esophageal cancer	1.07e-06	6.99e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—NOS3—esophageal cancer	1.04e-06	6.82e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PTGS2—esophageal cancer	1.04e-06	6.79e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—NOS3—esophageal cancer	1.04e-06	6.77e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PTGS2—esophageal cancer	1.01e-06	6.62e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CREBBP—esophageal cancer	9.88e-07	6.46e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—EP300—esophageal cancer	9.68e-07	6.32e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PTGS2—esophageal cancer	9.55e-07	6.24e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—PIK3CA—esophageal cancer	9.55e-07	6.24e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PTGS2—esophageal cancer	9.47e-07	6.19e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TP53—esophageal cancer	9.24e-07	6.03e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—NOS3—esophageal cancer	8.85e-07	5.78e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—EP300—esophageal cancer	8.64e-07	5.64e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PIK3CA—esophageal cancer	8.46e-07	5.53e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—EP300—esophageal cancer	8.43e-07	5.51e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PIK3CA—esophageal cancer	8.27e-07	5.4e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PTGS2—esophageal cancer	8.09e-07	5.29e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—EP300—esophageal cancer	7.95e-07	5.19e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—EP300—esophageal cancer	7.88e-07	5.15e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CREBBP—esophageal cancer	7.63e-07	4.98e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PIK3CA—esophageal cancer	7.16e-07	4.68e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—NOS3—esophageal cancer	6.83e-07	4.46e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—EP300—esophageal cancer	6.73e-07	4.4e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PIK3CA—esophageal cancer	6.39e-07	4.18e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PTGS2—esophageal cancer	6.25e-07	4.08e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PIK3CA—esophageal cancer	6.24e-07	4.08e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PIK3CA—esophageal cancer	5.88e-07	3.84e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PIK3CA—esophageal cancer	5.83e-07	3.81e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—EP300—esophageal cancer	5.2e-07	3.39e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PIK3CA—esophageal cancer	4.98e-07	3.25e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PIK3CA—esophageal cancer	3.84e-07	2.51e-06	CbGpPWpGaD
